Management of recurrent thrombosis in antiphospholipid syndrome.
One of the challenges of managing patients with antiphospholipid syndrome is the prevention of rethrombosis (secondary prophylaxis). Risk stratification, i.e. traditional cardiovascular and thrombosis risk factors, systemic autoimmune diseases, antiphospholipid antibody profile, and the intensity of anticoagulation are all relevant to the management of APS patients with recurrent thrombosis. The paper will review "state of the art" strategies for optimizing therapy for APS patients with recurrent thrombosis.
Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, nalli@bresciareumatologia.it.
Cecilia
C
Nalli
Laura
L
Andreoli
Cinzia
C
Casu
Angela
A
Tincani
D017152:Antibodies, Antiphospholipid / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D006801:Humans; D012307:Risk Factors; D055502:Secondary Prevention; D013927:Thrombosis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D015415:Biomarkers